Trial Profile
Phase 2 study of low-dose Afatinib maintenance therapy for patients with EGFR-mutated non-small-cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 12 Feb 2019 Status changed from recruiting to completed.
- 23 May 2016 New trial record